Author Archives: Iqra Mumal, MSc

Emerald Health Awarded 6 Patents for Potential Cannabis Treatments

Emerald Health Pharmaceuticals (EHP), the company developing the synthetic cannabis-derived EHP-101 as a treatment for scleroderma, has been granted six patents related to 25 new molecules derived from cannabidiol (CBD) and cannabigerol (CBG). The new patents were granted in Japan, Israel, Australia, and Russia. Both CBD…

IVIG Therapy Can Help Reduce Corticosteroid Dosage for Scleroderma-associated Myopathy, Study Finds

Intravenous antibodies can be used as add-on therapy to reduce the dosage of corticosteroids and achieve disease remission in people with scleroderma-associated myopathy (SScAM), or muscle disease, a study suggests. The study, “Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients,”…